Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis (RA) drug market will more than double by 2013, growing from $138 million in 2008 to $385 million in 2013. This growth will be fueled by a growing drug-treated population, increasing patient access to healthcare insurance, greater patient spending power and increased use of biological agents in RA treatment.

"A principal driver of growth in the Chinese RA market is the expanding patient population. We expect the number of patients eligible for drug therapy to increase 52 percent by 2013. During the same 2008-2013 time period, the drug-treated population will grow approximately 80 percent," stated Jing Wu, M.S., MBA.

The new Emerging Markets report entitled Rheumatoid Arthritis in China also finds that Western branded drug sales will command 54 percent of the market by 2013. The key drivers of this growth will be the increased uptake of currently available Western branded biologics and the launch of new biologics. The best opportunities for Western drug companies are in the launch and marketing of new biological agents that are easily administered and have novel mechanisms of action that achieve quicker onset of disease-modifying activity.

"We expect less competition from Chinese generic versions of new Western branded biologics than for small-molecule drugs for two reasons: biologics are harder to imitate than small chemical molecules and it is difficult to convince physicians that biosimilars have the same activity as the original brands," added Ms. Wu.

The report contains primary research of physicians and epidemiology study in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou -- and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou and Jinan.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Gisselle Morales                 Elizabeth Marshall   Decision Resources               Decision Resources, Inc.   781-296-2691                     781-296-2563   gmorales@dresources.com          emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Gisselle Morales, Decision Resources, +1-781-296-2691,
gmorales@dresources.com, or Elizabeth Marshall, Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Increasing Diagnosis Rates and Growing Use of Key Agents Such as Pfizer's Lyrica Will Drive Eight Percent Annual Growth in the Fibromyalgia Drug Market Through 2018

View Now